BIO · Bio-Rad Laboratories, Inc.
$372.51
+1.02% last session
End-of-day data · close of 2026-09-11
Market cap
$10B
Enterprise value
$10B
Trailing P/E
45.9
Forward P/E
36.8
Dividend yield
—
Beta
1.07
Avg volume
0M
Employees
7K
Daily Change %
1.02%
5 Days Change
-2.37%
10 Days Change
-2.37%
30 Days Change
5.82%
60 Days Change
27.31%
Month to Day Change
-1.05%
Year to Day Change
24.42%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-07
Latest call per bank · past 12 months
RBC Capital
Outperform$390
+5.8% vs priceCitigroup
Neutral$330
-10.5% vs priceWells Fargo
Equal-Weight$330
-10.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | RBC Capital | Maintains | Outperform | $370 → $390 |
| 2026-08-05 | Citigroup | Maintains | Neutral | $300 → $330 |
| 2026-08-05 | RBC Capital | Maintains | Outperform | $320 → $370 |
| 2026-08-05 | Wells Fargo | Maintains | Equal-Weight | $310 → $330 |
| 2026-05-01 | Wells Fargo | Maintains | Equal-Weight | $320 → $290 |
| 2026-04-07 | Citigroup | Downgrade | Buy → Neutral | $375 → $300 |
| 2026-02-16 | Wells Fargo | Maintains | Equal-Weight | $340 → $320 |
| 2025-10-30 | Citigroup | Maintains | Buy | $350 → $375 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.8% above the 50-day MA ($342.43).
- Price vs 200-day MA: Trading 22.8% above the 200-day MA ($303.33).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-3.97) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($390.34).
BIO Price Chart
Loading chart for BIO…
Fundamentals
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.